Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Jan 03, 2018
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-kisqali-received-fda-breakthrough-therapy-designation-initial-endocrine-based-treatment-premenopausal-women-hrher2-advanced-breast-cancer-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-kisqali-received-fda-breakthrough-therapy-designation-initial-endocrine-based-treatment-premenopausal-women-hrher2-advanced-breast-cancer-0